MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments. The novel diagnostic test will be the first immuno-MALDI test to measure the activity of multiple cancer-associated proteins in patients’ tumours. This approach has the potential to transform the selection of cancer treatments by providing direct insight into the mechanisms of disease progression and appropriate drug targets on a patient-by-patient basis.

Read the press release here.